LB PHARMACEUTICALS INC (LBRX) Form 8-K — Sep 3, 2026

$LBRXForm 8-KItems 5.02, 7.01, 9.01Filed Sep 3, 2026, 8:05 AM ET0001193125-26-381076Original filing

LB Pharmaceuticals Inc (Nasdaq: LBRX) announced on September 3, 2026 that Joseph M. Miller has been appointed Chief Financial Officer, effective September 2, 2026. The appointment was reported under Item 5.02 of an 8-K and accompanied by a press release. Miller brings more than two decades of biopharma finance experience, most recently as CFO of Aurinia Pharmaceuticals from April 2020 to March 2026, where he scaled the finance organization through the commercial launch of LUPKYNIS and an ex-U.S.

Key figures

Cfo Base Salary: 530000
Option Vesting: 4 years, 25% cliff at first anniversary then monthly
Non Coc Severance: 9 months salary continuation, 9 months COBRA
Inducement Option Shares: 200000
Change Of Control Severance: 1 year salary + 150% of target bonus, 12 months COBRA, equity acceleration
Cfo Target Bonus Percent Of Base: 40

Price after filing

1 day: +3.8%7 days: +0.3%30 days: -22.2%

Close on the filing date to close N calendar days later (from $47.52). Historical, not a forecast.

AI analysis

Red flags3 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.